| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Reported positive topline results from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia; New Drug Application submission planned by end of 2026 remains on track |
| 08 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
On September 8, 2026, Amylyx Pharmaceuticals, Inc. (the “Company”) entered into a Manufacturing and Supply Agreement (the “Bachem Manufacturing Agreement”) with Bachem Americas, Inc. (“Bachem”) and on September 1, 2026, the Company enter... |
| 20 Aug 2026 |
8-K: Entry into a Material Definitive Agreement
As representatives (the “Representatives”) of the several Underwriters |
| 18 Aug 2026 |
8-K: Other Events
Exhibit 99.1 Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia (PBH) Topline Data Conference Call August 18, 2026 Maggie, a mom and advocate living with post-bariatric hypoglycemia (PBH). Pancreatic islet cells |
| 18 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
LUCIDITY met FDA-agreed-upon primary endpoint; avexitide demonstrated a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared to placebo (p=0.000003) |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Last participant completed final study visit in the 16-week double-blind period of the pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia; topline data on track and anticipated in late August or early September 2026 |
| 04 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Amylyx Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 4, 2026 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders considered and voted on the three proposals set forth below, e... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Topline data readout from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia on track; anticipated in Q3 2026 |
| 24 Mar 2026 |
8-K: Regulation FD Disclosure
Exhibit 99.1 MARCH 2026 We have an audacious mission to develop novel therapies for diseases with high unmet needs, with a focus on serious and fatal endocrine conditions and neurodegenerative diseases. Maggie, a mom and advocate living ... |
| 03 Mar 2026 |
8-K: Results of Operations and Financial Condition
Recruitment of the pivotal Phase 3 LUCIDITY trial of avexitide in PBH is complete; continue to expect to randomize and dose last eligible participants in Q1 2026, with topline data anticipated in Q3 2026 |
| 08 Jan 2026 |
8-K: Regulation FD Disclosure; Other Events
Exhibit 99.1 JANUARY 2026 We have an audacious mission to develop novel therapies for diseases with high unmet needs, with a focus on serious and fatal neurodegenerative diseases and endocrine conditions. Maggie, a mom and advocate livin... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
Completion of recruitment for pivotal Phase 3 LUCIDITY trial of avexitide expected in Q1 2026, with topline data anticipated in Q3 2026 |
| 10 Sep 2025 |
8-K: Entry into a Material Definitive Agreement
As representatives (the “Representatives”) of the several Underwriters |
| 27 Aug 2025 |
8-K: Other Events
On August 27, 2025, Amylyx Pharmaceuticals, Inc. (the “Company”) announced it is discontinuing the ORION program of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO, also known as ursodoxicoltaurine]) in adults living with pro... |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
Completion of recruitment for pivotal Phase 3 LUCIDITY trial of avexitide in PBH expected in 2025, with topline data anticipated in first half of 2026 |
| 05 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Amylyx Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 5, 2025 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders considered and voted on the three proposals set forth below, e... |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition
Pivotal Phase 3 LUCIDITY trial of avexitide, a potential first-in-class GLP-1 receptor antagonist with FDA breakthrough therapy designation, underway in post-bariatric hypoglycemia (PBH); completion of recruitment expected in 2025, with ... |
| 04 Mar 2025 |
8-K: Results of Operations and Financial Condition
Pivotal Phase 3 LUCIDITY trial of avexitide, a potential first-in-class GLP-1 receptor antagonist, in post-bariatric hypoglycemia underway; completion of recruitment expected in 2025, with topline data anticipated in first half of 2026 |
| 10 Jan 2025 |
8-K: Entry into a Material Definitive Agreement
As representative (the “Representative”) of the several Underwriters |
| 30 Dec 2024 |
8-K: Regulation FD Disclosure
On December 30, 2024, Gubra A/S (“Gubra”) announced a collaboration with Amylyx Pharmaceuticals, Inc. (the “Company”) for the development of a potential novel long-acting GLP-1 receptor antagonist. |
Loading...